Indications on deck for Keytruda

Merck’s strategy for facing down growing competition in the PD-1 and PD-L1 landscape involves continuous expansion into new market segments for Keytruda, and there are still plenty for the market leader to capture.

Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) has been approved for 15 cancer types across different disease subsets and in various combinations, but an analysis of the anti-PD-1 mAb’s clinical trial line-up suggests that’s only the tip of the iceberg. ...